ArticleJournal of hypertension2025
Human umbilical cord mesenchymal stem cells improve the pregnancy outcomes of preeclampsia rats via inducing placental angiogenesis.
Article in Journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Umbilical Cord Mesenchymal Stem Cells Improve PINK1/PARKIN-Mediated Mitophagy Inhibition in Preeclampsia.Cell biochemistry and biophysics · 2026Article
- Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia is considered to be a serious complication unique to pregnancy caused by placental dysplasia. Although interventions such as antihypertensive drugs and magnesium sulfate can partially mitigate maternal risk, the ultimate remedy remains delivery. In recent years, mesenchymal stem cells (MSCs) have become promising therapeutic approach in the treatment of ischemic diseases. Therefore, this study aimed to investigate the effect of human umbilical cord mesenchymal stem cells (hucMSCs) on pregnancy outcomes and placental angiogenesis in N-nitro-L-arginine methyl ester (L-NAME) induced preeclampsia rats.
methodsThe expression of mesenchymal markers in hucMSCs was analyzed by flow cytometry. Multipotent differentiation of hucMSCs was identified, respectively. HucMSCs were injected into the preeclampsia rat by the tail vein. SBP was measured at the rat tail artery using an automatic noninvasive blood pressure monitor. The proteinuria levels were measured using the BCA method. RT-qPCR and ELISA were used to assess the mRNA expression and plasma concentrations of soluble FMS-like tyrosine kinase 1 (sFlt-1), placental growth factor (PLGF), and vascular endothelial growth factor (VEGF). Placental tissues were collected for immunohistochemistry and pathological analysis.
resultsHucMSCs were positive for CD90, CD73, and CD105, and could differentiate into osteoblasts, adipocytes and chondrocytes. PE rats treated with hucMSCs showed a lowering of SBP and proteinuria and a higher fetal and placental mass. The microvascular density (MVD), mRNA expression, and plasma concentrations of VEGF and PLGF were increased in the hucMSCs-treated group, while the sFlt-1 levels were decreased.
conclusionHucMSCs may promote placental angiogenesis and improve the pregnancy outcomes of preeclampsia rats by regulating the balance of pro-angiogenic and antiangiogenic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.